Sugi Predict

Sugi Predict / Compounds / SCHEMBL594390

SCHEMBL594390

SCHEMBL594390

N#Cc1cc([N+](=O)[O-])ccc1F

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ VCAM1 P19320 3/20 0.64
▸ ALDH1A1 P00352 8/20 0.56
▸ HIF1A Q16665 1/20 0.56
▸ LMNA P02545 6/20 0.55
▸ GAA P10253 3/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ XDH P47989 1/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ TSHR P16473 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ RECQL P46063 1/20 0.46
▸ BCL6 P41182 1/20 0.44
▸ BCOR Q6W2J9 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alcohol SCHEMBL27931607 0.89 VCAM1 (0.53) VCAM1ALDH1A1HIF1ALMNAGAA
SCHEMBL361867 0.85 VCAM1 (0.59) VCAM1ALDH1A1HIF1ALMNAGAA
SCHEMBL25837938 0.85 VCAM1 (0.59) VCAM1ALDH1A1HIF1ALMNAGAA
Fluoride SCHEMBL28618487 0.84 VCAM1 (0.57) VCAM1ALDH1A1HIF1ALMNAGAA
SCHEMBL697640 0.83 ALDH1A1 (0.58) VCAM1ALDH1A1HIF1ALMNAMEN1
SCHEMBL73860 0.82 VCAM1 (0.70) VCAM1ALDH1A1LMNAGAASMN1; SMN2
SCHEMBL16957219 0.81 ALDH1A1 (0.56) VCAM1ALDH1A1HIF1ALMNAMEN1
SCHEMBL4645678 0.81 ALDH1A1 (0.56) VCAM1ALDH1A1HIF1ALMNASMN1; SMN2
SCHEMBL27880249 0.81 ALDH1A1 (0.56) VCAM1ALDH1A1HIF1ALMNASMN1; SMN2
Fluoride SCHEMBL28259583 0.81 VCAM1 (0.68) VCAM1ALDH1A1LMNAGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 607 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137703-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER CANCER RESEARCH TECH LIMITED (GB) 2026-05-21 — — US disclosed
US-20260042782-A1 ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR C4 THERAPEUTICS, INC. (US) 2026-02-12 — — US disclosed
EP-4681715-A2 ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR C4 Therapeutics, Inc. (US) 2026-01-21 — — EP disclosed
US-20260014147-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2026-01-15 — — US disclosed
EP-4676926-A1 BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS ThirtyFiveBio Limited (GB) 2026-01-14 — — EP disclosed
EP-4076450-B1 ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR C4 THERAPEUTICS INC (US) 2025-12-10 — — EP disclosed
US-12486290-B2 Isoindolinone and indazole compounds for the degradation of EGFR C4 THERAPEUTICS, INC. (US) 2025-12-02 — — US disclosed
US-20250353835-A1 N-TETRAZOLYL ARYL UREA-BASED DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF HANGZHOU YIRUI PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2025-11-20 — — US disclosed
EP-4646402-A1 GPR35 MODULATORS ThirtyFiveBio Limited (GB) 2025-11-12 — — EP disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 — — US disclosed
EP-0593603-A1 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1994-04-27 — — EP disclosed
EP-0583288-A1 ANTIVIZAL DIBENZOTHIAZEPINONE DERIVATIVES THE WELLCOME FOUNDATION LIMITED (GB) 1994-02-23 — — EP disclosed
EP-0583317-A1 DIBENZOTHIAZEPINTHIONE AS ANTIVIRAL AGENTS THE WELLCOME FOUNDATION LIMITED (GB) 1994-02-23 — — EP disclosed
WO-1993000095-A2 BICYCLIC FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1993-01-07 — — WO disclosed
WO-1992019607-A1 DIBENZOTHIAZEPINTHIONE AS ANTIVIRAL AGENTS THE WELLCOME FOUNDATION LIMITED (GB) 1992-11-12 — — WO disclosed
WO-1992019277-A1 ANTIVIRAL DIBENZOTHIAZEPINONE DERIVATIVES THE WELLCOME FOUNDATION LIMITED (GB) 1992-11-12 — — WO disclosed
US-4200588-A ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC THE UPJOHN COMPANY (US) 1980-04-29 — — US disclosed
US-4130561-A Polycycloanilines THE UPJOHN COMPANY (US) 1978-12-19 — — US disclosed
US-4120899-A HYPOLIPEDEMIC, ANTIATHEROSCLEROTIC THE UPJOHN COMPANY (US) 1978-10-17 — — US disclosed
US-4036977-A HYPOLIPEDEMIC AND ANTIATHEROSCLEROTIC PROPERTIES THE UPJOHN COMPANY (US) 1977-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137703-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER EGFR, KRAS, O60361 VCAM1 2182/4885ALDH1A1 999/4885HIF1A 3360/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 VCAM1 3463/4885ALDH1A1 959/4885HIF1A 2279/4885
US-12486290-B2 Isoindolinone and indazole compounds for the degradation of EGFR EGFR, ERBB2, ERBB3 VCAM1 4268/4885ALDH1A1 2283/4885HIF1A 2245/4885
US-20260014147-A1 STAT6 DEGRADERS STAT6, NCOR1, CBR1 VCAM1 2152/4885ALDH1A1 1790/4885HIF1A 900/4885
US-20260042782-A1 ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR EGFR, ERBB2, ERBB3 VCAM1 4613/4885ALDH1A1 2446/4885HIF1A 2724/4885
US-20250353835-A1 N-TETRAZOLYL ARYL UREA-BASED DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF BDKRB1, BDKRB2, UTS2R VCAM1 187/4885ALDH1A1 2190/4885HIF1A 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.